Through patent-centric innovation, Novo Nordisk brings advanced
treatments to people living with haemophilia and rare bleeding
disorders. With a broad portfolio of innovative products and a focused
clinical pipeline, we engage with the scientific community to share
knowledge and thus improve haemophilia care.
Science is part of our commitment to changing haemophilia.
Novo Nordisk haemophilia research
At Novo Nordisk we are committed to changing haemophilia through
pioneering research - working towards the next breakthrough.
Through patent-centric innovation, Novo Nordisk brings advanced
treatments to people living with haemophilia and rare bleeding
disorders. With a broad portfolio of innovative products and a
focused clinical pipeline, we engage with the scientific community
to share knowledge and thus improve haemophilia care.
Science
is part of our commitment to changing haemophilia.
Novo Nordisk haemophilia research
At Novo Nordisk we
are committed to changing haemophilia through pioneering research -
working towards the next breakthrough.
Building on our
experience in protein and peptide design, Novo Nordisk has continued
to discover and develop effective and safe medicines for people with
haemophilia and other rare bleeding disorders.
Through patent-centric innovation, Novo Nordisk brings advanced
treatments to people living with haemophilia and rare bleeding
disorders. With a broad portfolio of innovative products and a
focused clinical pipeline, we engage with the scientific community
to share knowledge and thus improve haemophilia care.
Science
is part of our commitment to changing haemophilia.
Novo Nordisk haemophilia research
At Novo Nordisk we
are committed to changing haemophilia through pioneering research -
working towards the next breakthrough.
Building on our experience in protein
and peptide design, Novo Nordisk has continued to discover and
develop effective and safe medicines for people with haemophilia and
other rare bleeding disorders.
Building on our
experience in protein and peptide design, Novo Nordisk has continued
to discover and develop effective and safe medicines for people with
haemophilia and other rare bleeding disorders.
Our successful research programmes mean that, today, we offer
innovative products and have a rich pipeline of next-generation
longer-acting and efficacious medicines capable of delivering
effective prophylaxis and reducing the treatment burden for patients.
